Long-term follow-up (LTFU) is a defining feature of oncology and cell and gene therapy (CGT) trials, where post-treatment monitoring often spans 2 to 15 years. These extended timelines allow regulators to assess long-term safety and efficacy from detecting delayed adverse...
Elaina Haeuber
Oncology & Hematology
Are You Engaging a CRO at the Right Point in Your Drug Development Program?
The traditional entry point for clinical research organization (CRO) engagement is delivery of the first clinical research study. However, companies with limited internal resources may benefit from engaging with a CRO as early as possible to leverage the full breadth...
Clinical Development
Celebrating World Cancer Day: An Interview with Leading Oncology Experts
Every year on February 4th, the world comes together to recognize World Cancer Day, a global initiative led by the Union for International Cancer Control (UICC). This day unites individuals, communities, and organizations in the fight against cancer while raising...
Clinical Development
Bringing an Oncology Asset to Market: In-House vs Outsource?
During the multifaceted journey of bringing a promising therapeutic to market, sponsors are faced with a critical choice—whether to manage asset development in-house or to outsource to a clinical research organization (CRO) partner. This decision can influence timelines, costs, control...